Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06089967 · ClinicalTrials.gov registry record
Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 30
- Enrollment target
NCT06089967 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 30 participants.
The verdict
NCT06089967 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The purpose of this project is to collect body samples like blood and tissue and health information from people receiving immune-based treatment for cancer. The body samples and health information will be stored for future research to understand more about side effects related to immune-based treatments for cancer.
Interventions
- OTHER Medical chart review
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-10-05 |
| Est. Completion | 2024-12-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06089967
The ClinicalTrials.gov registry entry for NCT06089967 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Medical chart review is the first listed.
NCT06089967 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06089967 about?
NCT06089967 is a clinical study titled "Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy". The purpose of this project is to collect body samples like blood and tissue and health information from people receiving immune-based treatment for cancer. The body samples and health information will be stored for future research to understand more about side effects related to immune-based treatm...
What is the current status of trial NCT06089967?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2022-10-05. Estimated completion is 2024-12-06.
What interventions are being tested in trial NCT06089967?
The interventions under investigation include: Medical chart review (OTHER).
Who is sponsoring clinical trial NCT06089967?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.